Resultados de la búsqueda 41-50 of 12186 for 5-Amino-1MQ
The primary endpoint is EFS and 774 eligible and evaluable patients are anticipated to enroll over approximately 5 years. Key secondary endpoints are ...
... (5) advanced, unresectable colorectal cancer, (6) advanced, unresectable ... The primary endpoint is EFS and 774 eligible and evaluable patients are anticipated to ...
¿Te gustaría hacer una donación deducible de impuestos y ser parte de una investigación de vanguardia y de una atención médica que transforma la medicina?
This phase I trial evaluates the safety, effectiveness, and best dose of onvansertib for the treatment of patients with chronic myelomonocytic leukemia that ...
All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small ...
The five year follow-up period will ensure robust survival data for correlations with clinical, tumor, and treatment variables. The target of 2,500 patients ...
Scottsdale/Phoenix, Ariz., Rochester, Minn. This is a peripheral blood Collection Protocol to study the T-cell immune responses of patients with malignancies ...
To determine the effectiveness of the ARTISAN Aphakia lens in the treatment of aphakia and to precisely define the associated risks and, if possible, ...
½ can be used to sort gliomas into five categories, each with different clinical features and outcomes. New regimen offers longer disease control and a ...
Mayo Clinic no respalda compañías ni productos. Las recaudaciones de los avisos comerciales financian nuestra misión sin fines de lucro.
Consulta estos éxitos de venta y ofertas especiales en libros y boletines informativos de Mayo Clinic Press.